Telehealth vs In-Person Assessments for Brain Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase IV trial compares patient satisfaction with telehealth versus in-person neuro-oncology assessments among glioma patients receiving oral chemotherapy. Gliomas are the most common primary central nervous system cancer and are associated with a high symptom burden, such as drowsiness, fatigue, memory difficulty, and difficulty communicating. Care at a high volume center is associated with an overall survival benefit, however, many patients may have physical or financial difficulties preventing access to these centers. Telehealth visits use computers, cameras, videoconferencing, the internet, satellite, and wireless communications to deliver healthcare, while in-person visits require the interaction to take place in the physical presence of someone else. Telehealth neuro-oncology assessments may be preferable compared to in-person assessments in glioma patients receiving oral chemotherapy.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
Is temozolomide safe for humans?
Temozolomide is generally considered safe and well-tolerated, with common side effects like fatigue, nausea, and vomiting. However, it can cause serious blood-related side effects, such as myelodysplastic syndrome (a bone marrow disorder) and aplastic anemia (a condition where the body stops producing enough new blood cells), though these are rare.12345
What makes the drug Temozolomide unique for treating brain tumors?
Temozolomide is unique because it can cross the blood-brain barrier, which many other drugs cannot do, making it effective for treating brain tumors. It is available in both oral and intravenous forms, providing flexibility for patients who may have difficulty swallowing pills or need alternative administration methods.16789
What data supports the effectiveness of the drug Temozolomide for brain tumors?
Temozolomide has been shown to improve survival in patients with glioblastoma when used with radiotherapy, and it is effective for various brain tumors, including glioma and primary CNS lymphoma. It has demonstrated high response rates in recurrent anaplastic astrocytoma and is considered a useful agent for treating a variety of cancers.69101112
Who Is on the Research Team?
Ugur T Sener, M.D.
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for glioma patients undergoing oral chemotherapy who may benefit from telehealth assessments. Ideal participants are those with brain tumors like glioblastoma, oligodendroglioma, or astrocytoma and experience high symptom burden.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive temozolomide orally once daily on days 1-5 of each cycle, with cycles repeating every 28 days for up to 6 cycles. Assessments alternate between telehealth and in-person visits after each cycle.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up occurring 30 days after the study intervention.
What Are the Treatments Tested in This Trial?
Interventions
- Assessment
- Questionnaire Administration
- Telemedicine Visit
- Temozolomide
Temozolomide is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor